NIAID works closely with other federal agencies and global organizations to encourage research and efforts to prevent, treat, and diagnose mycobacterial infections.
In 1991, the Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, launched the Federal Tuberculosis (TB) Task Force in response to a 20 percent surge in TB cases in the United States between 1985 and 1992. The Federal TB Task Force has undertaken the challenge of controlling TB in the United States by maintaining control of TB, speeding the decline of TB through targeted tuberculin skin testing and treatment of latent TB infection, and supporting basic and applied research to develop better diagnostic, treatment, and prevention tools as well as related behavioral and social research targeted toward understanding and improving patient adherence with therapy. Visit the Division of Tuberculosis Elimination and the Federal TB Task Force.
Aeras Global TB Vaccine Foundation, which is a non-profit organization dedicated to developing effective TB vaccine regimens. Visit the Aeras Global TB Vaccine Foundation.
EDCTP aims to accelerate the development of new or improved drugs, vaccines and microbicides against HIV/AIDS, malaria, and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa. Visit the European and Developing Countries Clinical Trials Partnership.
FIND is dedicated to developing rapid, accurate, and affordable diagnostic tests through public-private partnerships. Visit the Foundation For Innovative New Diagnostics.
Eli Lilly and Company, as part of their philanthropic effort in multidrug-resistance TB, launched the Lilly Not-For-Profit Partnership for TB Early Phase Drug Discovery in partnership with NIAID. This unique endeavor is designed to accelerate discovery and development of new drugs to fight TB and make treatment of TB more effective, accessible, and affordable. Visit the Eli Lilly and Company.
NTMir provides insight into the disease caused by nontuberculous mycobacteria (NTM) and empowers patients to participate in their own treatment. Visit the Nontuberculous Mycobacteria Information and Research.
The Global Alliance for TB Drug Development is a not-for-profit product development partnership accelerating the discovery and development of new TB drugs. Visit the Global Alliance for TB Drug Development.
WHO is working to dramatically reduce the burden of TB and halve TB deaths and prevalence by 2015 through its Stop TB Strategy and by supporting the Global Plan to Stop TB. The Stop TB Partnership was established in 2000 to realize the goal of eliminating TB as a public health problem and, ultimately, to obtain a world free of TB. Visit the World Health Organization.
NHDP is the epicenter of Hansen's disease (leprosy) care, research, and information in the United States. The program included patient care at its facility at the Ochsner Medical Center in Baton Rouge, Louisiana, and an ambulatory care network with 11 clinics in seven States and Puerto Rico. It also makes referrals for treatment and consultation with private sector physicians and referrals for patients with Hansen's disease-related complications. It educates medical professionals about Hansen's disease and treatment advances, conducts Hansen's disease biomedical research, and reaches out to medical professionals with a comprehensive Hansen's disease training program. Visit the National Hansen’s Disease Program.
In addition, NIAID also interacts with notable organizations to combat mycobacterial infections.
ALA was founded in 1904 to fight TB. The National Association for the Study and Prevention of Tuberculosis, as it was known then, was the first nationwide voluntary health organization aimed at conquering a specific disease. Visit the American Lung Association.
ASM is the oldest and largest single life science membership organization in the world. The Society’s Division U is comprised of members involved with mycobacteria and its diseases on a research, diagnostic, public health, or teaching basis. ASM's mission is to encourage and facilitate information dissemination on mycobacterial biology, new diagnostics, therapies, and vaccines for mycobacterial diseases. Visit the American Society for Microbiology and Division U.
ATS anchors its core values in preventing respiratory disease and advancing the care of patients with disorders of the lung and thorax, critical illnesses, and sleep-related conditions. ATS sets research priorities and shares funding responsibilities with other medical, research, clinical, professional, corporate, patient, and nonprofit health organizations with interests in pulmonary and critical care diseases and disorders. Visit the American Thoracic Society.
IDSA represents physicians, scientists, and other healthcare professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases. Visit the Infectious Diseases Society of America.
IUATLD is a nonprofit, non-governmental voluntary organization, founded in 1920. Its members, organizations, and people throughout the world are dedicated to preventing and controlling tuberculosis and lung disease, to disseminating information about the hazards of smoking, and to the promoting overall community health. Visit the International Union Against Tuberculosis and Lung Disease.
back to top
Last Updated November 02, 2010